The 2008 Lancet paper of Paolo Macchiarini and Martin Birchall about the world first trachea transplant might end up retracted. Until recently, the journal’s editor Richard Horton used to ignore and suppress “non peer-reviewed” evidence, but due to combined pressure of activism, media and politics, things started to move.
Paediatric surgeon Paolo De Coppi claims to grow all possible internal organs in his lab at UCL. Though his career started with his association with Macchiarini, and their regenerative medicine ideas sound strangely similar, De Coppi is celebrated as a modest genius poised to save lives of uncounted children, and the funding money flows.
A “defamation Complaint” was lodged with Google, against 6 of my articles and one cartoon. Each of them affects to some degree the British laryngologist Martin Birchall, professor at UCL and former close associate of scandal surgeon Paolo Macchiarini. I also show that Birchall and UCL even now continue researching plastic tracheas on pigs, for future use in humans patients. This grant is presently funded by UK government.
Videregen, the Liverpool-based company which bought the trachea regeneration patent from UCL, deployed lawyers against the academics Patricia Murray and Raphael Levy, precisely via their employer University of Liverpool. Main issue is the parliamentary submission by Levy and Murray, subject to absolute privilege. Yet Videregen also cites from the confidential notice of suspected research misconduct Murray and Levy submitted in good faith to UCL.
In 2017, UCL invited an external expert commission to investigate the deadly trachea transplants performed by the former UCL honorary professor Paolo Macchiarini. An already sacked UCL nanotechnology professor, Alexander Seifalian, whose lab made the two UCL plastic POSS-PCU tracheas in 2011, was announced as the main culprit on UCL side. All this despite Seifalian’s having had no clinical role, training or ambitions, as he professed in his interview to the investigative committee, which I now obtained.
What with the EU phase 2 clinical trial TETRA going nowhere, the technology’s owner, Liverpool-based company Videregen decided to seek new clinical partners. Surgeons and universities from outside the EU are invited to test Videregen’s trachea transplant technology, which was originally developed together with Paolo Macchiarini by the UCL laryngologist and paid Videregen advisor Martin Birchall.
Imagine you are Martin Birchall, laryngologist and ENT surgeon, star of regenerative medicine at UCL and trachea transplant enthusiast. You and your business partner Videregen need to explain to EU bureaucrats why your technology of decellurised cadaveric trachea is perfectly safe, what with all the dead patients of yours and your former best friend Paolo Macchiarini. Yet both your trachea transplant pigs die. EU authorities however accept this as proof that your method is safe!
The European Commission admitted that their €6.8 mn phase 2 clinical trial TETRA with cadaveric tracheas, led by the UCL laryngologist Martin Birchall is unlikely to ever recruit any patients. In January 2019, the status was changed to “grant agreement terminated”